Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
This shift creates an opportunity to build eating habits aligned with your health goals, rather than fighting constant hunger signals
CT-388 (enicepatide), a dual GLP-1/GIP injectable, delivered 22.5% weight loss in Phase 2 with 54% of patients on the highest dose achieving a BMI under 30
What should I do if the solution turns cloudy or changes color
Altered gut motility these medications affect the movement of the entire gastrointestinal tract, not just the stomach
In the meantime, Eli Lilly, as well as pharmaceutical companies Novo Nordisk and Pfizer, are racing to be the first to market with the oral version of these weight-loss drugs as doctors believe it will be more palatable to people than injections
